Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

What Is the Life Expectancy for Someone With HCM?

At a Glance

The life expectancy for someone with hypertrophic cardiomyopathy (HCM) is generally normal or near-normal. Thanks to modern treatments, regular monitoring, and specialized cardiac care, the vast majority of patients can manage their symptoms and live a long, active life.

If you have just been diagnosed with hypertrophic cardiomyopathy (HCM), your most urgent question is likely whether this condition will shorten your life. The short and reassuring answer is: for the vast majority of patients, no. With modern medical treatments, regular monitoring, and specialized care, people with HCM can achieve a normal or near-normal life expectancy that is comparable to the general population. [1][2] While achieving a normal lifespan is an incredible medical triumph, it is important to acknowledge that living with HCM still takes work. It may involve daily medications, dealing with fatigue, and routine doctor visits, but with the right care, you can plan for a long future.

How the Outlook Has Changed

Historically, HCM was often viewed as a grim diagnosis with a high risk of severe complications. This outdated view was based on older statistics collected before modern screening and treatments were widely available. Today, cardiovascular care has completely transformed the landscape for HCM patients. Research following patients over the long term shows that early diagnosis and guideline-directed treatment drastically improve survival rates. [1]

This shift in understanding also applies to your lifestyle. In the past, HCM patients were often strictly forbidden from participating in sports due to fears of overworking the heart. Today, modern guidelines frequently encourage safe, mild-to-moderate physical activity, allowing patients to live much fuller, more active lives.

Why Modern Care is So Effective

A normal lifespan is achievable today because doctors have highly effective tools to prevent complications and manage daily symptoms. [3][4]

  • Implantable Cardioverter-Defibrillators (ICDs): One of the biggest historical risks of HCM was sudden cardiac death (SCD) caused by dangerously fast heart rhythms (arrhythmias). Today, cardiologists use specialized risk calculators, such as the HCM-Risk SCD score, to identify patients who might be at a higher risk. [5][6] For those individuals, a small device called an ICD is implanted under the skin. An ICD constantly monitors the heart and can instantly deliver a shock to correct a dangerous rhythm, drastically reducing the risk of sudden cardiac death and contributing to sustained survival. [7][8]
  • Monitoring for Atrial Fibrillation (AFib): Because the heart muscle is stiff, HCM patients are at a higher risk for developing Atrial Fibrillation, a chaotic rhythm in the upper chambers of the heart. AFib is a major focus of modern HCM care because it can increase the risk of blood clots and stroke. [9][10] By using wearable monitors to catch AFib early, doctors can prescribe blood thinners to effectively neutralize this stroke risk.
  • Targeted Medications: Decades of research have yielded specialized drugs that help the heart relax and function more efficiently. A new, innovative class of medications known as cardiac myosin inhibitors (such as mavacamten and aficamten) has recently been introduced. These drugs target the specific disease mechanisms of HCM at a cellular level, improving blood flow and overall quality of life. [11][12]
  • Septal Reduction Therapies: For patients whose thickened heart muscle physically blocks blood from leaving the heart (a condition called obstructive HCM), and who remain highly symptomatic despite taking medications, procedures can be done to thin the excess tissue. [13] There are two main approaches: surgical septal myectomy (an open-heart surgery to carefully shave away the thickened muscle) and alcohol septal ablation (a minimally invasive procedure using a catheter in the leg to shrink the muscle). Studies tracking patients over 15 years show that long-term survival rates after these procedures are excellent, mirroring the life expectancy of people of the exact same age and sex in the general public who do not have HCM. [14][15]

Genetics and Protecting Your Family

Because HCM is primarily a genetic condition, a long, normal life for you also means thinking about your family’s health. First-degree relatives (your parents, siblings, and children) have a 50% chance of inheriting the genetic variant that causes HCM. Working with a genetic counselor and ensuring your immediate family receives regular screening (such as clinical echocardiograms or genetic testing) is a crucial, standard part of modern HCM care. [11][1]

The Importance of Specialized Care

While the overall prognosis for HCM is excellent, the disease is complex and affects everyone differently. [16] Some variations of the condition (like apical HCM) might have lower rates of heart failure [17], while other factors, such as biological sex, can influence disease progression. For instance, studies show that women sometimes present with more advanced symptoms at diagnosis and may face a higher risk of complications, highlighting the need for highly personalized care. [18][19]

Because HCM is a specialized field, long-term success is closely tied to being evaluated at a dedicated HCM center. A multidisciplinary team can tailor a treatment plan specific to your genetics, your heart’s structure, and your daily symptoms. [11][20] By staying engaged with your care team, carefully monitoring for changes in how you feel, and following modern clinical guidelines, you can plan for the future with confidence.

Common questions in this guide

Can you live a long life with hypertrophic cardiomyopathy?
Yes. With modern medical treatments, regular monitoring, and specialized cardiovascular care, the vast majority of people with HCM can achieve a normal or near-normal life expectancy.
Do I need an ICD if I have HCM?
Not everyone with HCM needs an implantable cardioverter-defibrillator (ICD). Your cardiologist will calculate your specific risk for sudden cardiac death to determine if an ICD is recommended for your safety.
What is the difference between obstructive and non-obstructive HCM?
Obstructive HCM occurs when the thickened heart muscle physically blocks blood from leaving the heart. In non-obstructive HCM, the muscle is thickened but does not restrict blood flow. Your specific type directly affects your long-term treatment plan.
Can people with HCM exercise?
Yes, modern guidelines often encourage safe, mild-to-moderate physical activity for people with HCM. You should work closely with your cardiology care team to determine the safest level of exercise for your specific condition.
Should my family be tested if I have hypertrophic cardiomyopathy?
Because HCM is a genetic condition, your parents, siblings, and children have a 50% chance of inheriting the genetic variant. It is highly recommended to work with a genetic counselor to arrange clinical screening or genetic testing for your immediate family.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my echocardiogram and family history, what is my calculated risk score for sudden cardiac death, and do I need an ICD?
  2. 2.Do I have obstructive or non-obstructive HCM, and how does that specific subtype affect my long-term treatment plan?
  3. 3.What specific symptoms or changes in how I feel—like new chest pain, dizziness, or palpitations—should prompt me to contact your office versus going to the emergency room?
  4. 4.How often should I undergo a Holter monitor test to check for silent arrhythmias like Atrial Fibrillation?
  5. 5.Would I benefit from seeing a specialized multidisciplinary HCM center or genetic counselor to discuss screening for my children and siblings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    The Diagnosis and Treatment of Hypertrophic Cardiomyopathy.

    Möbius-Winkler MN, Laufs U, Lenk K

    Deutsches Arzteblatt international 2024; (121(24)):805-811.

    PMID: 39377928
  2. 2

    Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now.

    Maron BJ, Rowin EJ, Maron MS, Braunwald E

    The American journal of medicine 2017; (130(2)):119-123 doi:10.1016/j.amjmed.2016.09.015.

    PMID: 27746287
  3. 3

    The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

    Fitzgerald P, Kusumoto F

    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2018; (52(3)):403-408 doi:10.1007/s10840-018-0433-0.

    PMID: 30097789
  4. 4

    Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae-A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy.

    Dorobantu LF, Iosifescu TA, Ticulescu R, et al.

    Journal of clinical medicine 2022; (11(11)) doi:10.3390/jcm11113083.

    PMID: 35683470
  5. 5

    Long-term incidence of implantable cardioverter-defibrillator therapy in patients with hypertrophic cardiomyopathy: analysis of appropriate and inappropriate interventions.

    Christensen EB, Vissing CR, Silajdzija E, et al.

    Heart (British Cardiac Society) 2025; (111(12)):575-582 doi:10.1136/heartjnl-2024-325020.

    PMID: 39832893
  6. 6

    International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).

    O'Mahony C, Jichi F, Ommen SR, et al.

    Circulation 2018; (137(10)):1015-1023 doi:10.1161/CIRCULATIONAHA.117.030437.

    PMID: 29191938
  7. 7

    Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy.

    Maron MS, Steiger N, Burrows A, et al.

    JACC. Clinical electrophysiology 2020; (6(8)):1019-1021 doi:10.1016/j.jacep.2020.03.015.

    PMID: 32819515
  8. 8

    Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.

    Thavikulwat AC, Tomson TT, Knight BP, et al.

    Journal of cardiovascular electrophysiology 2016; (27(8)):953-60 doi:10.1111/jce.13005.

    PMID: 27138377
  9. 9

    Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.

    Dicorato MM, Citarelli G, Mangini F, et al.

    Biomedicines 2025; (13(5)) doi:10.3390/biomedicines13051256.

    PMID: 40427081
  10. 10

    Hypertrophic cardiomyopathy.

    Santos Mateo JJ, Sabater Molina M, Gimeno Blanes JR

    Medicina clinica 2018; (150(11)):434-442 doi:10.1016/j.medcli.2017.09.013.

    PMID: 29150126
  11. 11

    Current management of hypertrophic cardiomyopathy.

    Sikand N, Stendahl J, Sen S, et al.

    BMJ (Clinical research ed.) 2025; (389()):e077274 doi:10.1136/bmj-2023-077274.

    PMID: 40425241
  12. 12

    Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.

    Młynarska E, Radzioch E, Dąbek B, et al.

    Biomedicines 2024; (12(12)) doi:10.3390/biomedicines12122675.

    PMID: 39767581
  13. 13

    Through Thick and Thin: What Are the Septal Thickness Limits for Alcohol Septal Ablation?

    Fifer MA

    Circulation. Cardiovascular interventions 2016; (9(3)):e003588.

    PMID: 26884613
  14. 14

    Survival After Myectomy for Obstructive Hypertrophic Cardiomyopathy: What Causes Late Mortality?

    Nguyen A, Schaff HV, Nishimura RA, et al.

    The Annals of thoracic surgery 2019; (108(3)):723-729 doi:10.1016/j.athoracsur.2019.03.026.

    PMID: 30978316
  15. 15

    Results of Ten-Year Follow-Up of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy.

    Kashtanov M, Rzhannikova A, Chernyshev S, et al.

    The International journal of angiology : official publication of the International College of Angiology, Inc 2018; (27(4)):202-207 doi:10.1055/s-0038-1675213.

    PMID: 30410291
  16. 16

    Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.

    Obayashi Y, Kato T, Shiomi H, et al.

    Circulation. Heart failure 2026; (19(3)):e013977 doi:10.1161/CIRCHEARTFAILURE.125.013977.

    PMID: 41636023
  17. 17

    Clinical Characteristics and Outcomes in Patients With Apical and Nonapical Hypertrophic Cardiomyopathy.

    Chen QF, Zou J, Katsouras CS, et al.

    Journal of the American Heart Association 2024; (13(19)):e036663 doi:10.1161/JAHA.124.036663.

    PMID: 39291501
  18. 18

    Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment.

    Butters A, Lakdawala NK, Ingles J

    Current heart failure reports 2021; (18(5)):264-273 doi:10.1007/s11897-021-00526-x.

    PMID: 34478112
  19. 19

    Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

    Chen YZ, Zhao XS, Yuan JS, et al.

    Biology of sex differences 2022; (13(1)):37 doi:10.1186/s13293-022-00447-x.

    PMID: 35799208
  20. 20

    Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.

    Batzner A, Pfeiffer B, Neugebauer A, et al.

    Journal of the American College of Cardiology 2018; (72(24)):3087-3094 doi:10.1016/j.jacc.2018.09.064.

    PMID: 30545446

This page provides general information about life expectancy and treatments for hypertrophic cardiomyopathy. It is not a substitute for professional medical advice, diagnosis, or treatment from your cardiologist.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.